Nucleic Acid Therapeutics

Papers
(The H4-Index of Nucleic Acid Therapeutics is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Assessing Hybridization-Dependent Off-Target Risk for Therapeutic Oligonucleotides: Updated Industry Recommendations129
Knockdown of Circular RNAs Using LNA-Modified Antisense Oligonucleotides103
Combined 20-Hydroxyecdysone and Antisense-Mediated Exon Skipping Improve Functional Outcomes in a Mouse Model of Duchenne Muscular Dystrophy87
SIDT2 Inhibits Phosphorothioate Antisense Oligonucleotide Activity by Regulating Cellular Localization of Lysosomes77
Quantification of mRNA Decay Rates in HeLa and SH-SY5Y Cell Lines Reveals Novel Properties of Membrane Protein Coding Transcripts48
Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates47
Therapeutic siRNA Loaded to RISC as Single and Double Strands Requires an Appropriate Quantitative Assay for RISC PK Assessment42
Correction to: Understanding and Rescuing the Splicing Defect Caused by the Frequent ABCA4 Variant c.4253 + 43G>A Underlyin38
Challenges of Assessing Exon 53 Skipping of the Human DMD Transcript with Locked Nucleic Acid-Modified Antisense Oligonucleotides in a Mouse Model for Du30
Screening Splice-Switching Antisense Oligonucleotides in Pancreas-Cancer Organoids24
Design and In Vitro Evaluation of a Novel Antisense Oligonucleotide for Treatment of BK Virus Infection20
Reversible Aptamer Staining, Sorting, and Cleaning of Cells (Clean FACS) with Antidote Oligonucleotide or Nuclease Yields Fully Responsive Cells20
Improvements to Hybridization-Ligation ELISA Methods to Overcome Bioanalytical Challenges Posed by Novel Oligonucleotide Therapeutics19
Inhibition of Epidermal Growth Factor Receptor Signaling by Antisense Oligonucleotides as a Novel Approach to Epidermal Growth Factor Receptor Inhibition19
Considerations for the Terminal Sterilization of Oligonucleotide Drug Products19
Cross-Species Translation of Biophase Half-Life and Potency of GalNAc-Conjugated siRNAs18
Near Sequence Homology Does Not Guarantee siRNA Cross-Species Efficacy17
Sequence- and Structure-Dependent Cytotoxicity of Phosphorothioate and 2′- O -Methyl Modified Single-Stranded Oligonucleotides17
0.77124309539795